3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pain
6
Neoplasms
6
Cancer Pain
6
Pain, Intractable
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Vesico-Ureteral Reflux
1
Ureteral Neoplasms
1
Thrombocythemia, Essential
1
Sigmoidal Tumour
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Postoperative
1
Nephrolithiasis
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Mucositis
1
Monoclonal Gammopathy of Undetermined Significance
1
Interventions
Tea
1
Sufentanil
1
Morphine
1
Ketorolac
1
Ibuprofen
1
Anti-Inflammatory Agents, Non-Steroidal
1
Analgesia, Patient-Controlled
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Inflammation
×
Morphine
×
Clear all
NCT01367418
2012-03-19
AIMS
Örebro University, Sweden
Phase 3
Completed
26 enrolled